Immunohistochemical staining with non-phospho β-catenin as a diagnostic and prognostic tool of COX-2 inhibitor therapy for patients with extra-peritoneal desmoid-type fibromatosis.
Immunohistochemical staining with non-phospho β-catenin as a diagnostic and prognostic tool of COX-2 inhibitor therapy for patients with extra-peritoneal desmoid-type fibromatosis.
复制标题
非磷酸β-catenin的免疫组织化学染色是针对腹膜外脱乳突型纤维瘤病患者的COX-2抑制剂治疗的诊断和预后工具。
DOI：
10.1186/s13000-017-0654-z
复制
发表时间：
2017-08-29
影响因子：
2.6
通讯作者：
Ishiguro N
中科院分区：
文献类型：
--
作者：
Sakai T;Nishida Y;Hamada S;Koike H;Ikuta K;Ota T;Ishiguro N
传统的抗β-catenin抗体免疫组化染色已被应用于韧带样型纤维瘤病（DF）的诊断工具。本研究旨在评价抗非磷酸化β-catenin抗体免疫组化染色对DF的诊断和预后价值，与常规抗β-catenin抗体相比，其可能更准确地反映DF的侵袭性。2003年至2015年，40例腹膜外散发性DF患者前瞻性接受美洛昔康或塞来昔布（一种考克斯-2抑制剂）治疗。根据实体瘤疗效评价标准（RECIST）评价该治疗的疗效。对福尔马林固定的材料进行免疫组织化学染色以评估β-catenin和非磷酸化β-catenin的表达，并将阳性分组为阴性、弱、中等和强。从冷冻组织或福尔马林固定的材料中分离DNA，并通过直接测序确定CTNNB 1突变状态。在接受考克斯-2抑制剂治疗的40例患者中，1例完全缓解，12例部分缓解，7例病情稳定，20例病情进展。CTNNB 1突变位点在40例中有22例（55%）被检测到：T41 A（17例）、S45 F（3例）、T41 I和S45 P（各1例）。非磷酸化β-连环蛋白的阳性核表达与桑格法检测到的CTNNB 1阳性突变状态显着相关（p = 0.025），且考克斯-2抑制剂治疗的结局较差（p = 0.022）。相比之下，β-连环蛋白的核表达与CTNNB 1突变状态（p = 0.43）或考克斯-2抑制剂治疗的结果（p = 0.38）均无显著相关性。非磷酸化β-catenin的核表达可能更能反映DF的生物学行为，非磷酸化β-catenin的免疫组化染色可作为DF患者考克斯-2抑制剂治疗的更有用的诊断和预后工具。
Immunohistochemical staining with conventional anti-β-catenin antibody has been applied as a diagnostic tool for desmoid-type fibromatosis (DF). This study aimed to evaluate the diagnostic and prognostic value of immunohistochemical staining with anti-non-phospho β-catenin antibody, which might more accurately reflect the aggressiveness of DF, in comparison to the conventional anti-β-catenin antibody. Between 2003 and 2015, 40 patients with extra-peritoneal sporadic DF were prospectively treated with meloxicam or celecoxib, a COX-2 inhibitor, therapy. The efficacy of this treatment was evaluated according to Response Evaluation Criteria in Solid Tumors (RECIST). Immunohistochemical staining was performed on formalin-fixed material to evaluate the expression of β-catenin and non-phospho β-catenin, and the positivity was grouped as negative, weak, moderate, and strong. DNA was isolated from frozen tissue or formalin-fixed materials, and the CTNNB1 mutation status was determined by direct sequencing. Of the 40 patients receiving COX-2 inhibitor treatment, there was one with complete remission, 12 with partial remission, 7 with stable disease, and 20 with progressive disease. The mutation sites in CTNNB1 were detected in 22 (55%) of the 40 cases: T41A (17 cases), S45F (3 cases), and T41I and S45P (1 each). The positive nuclear expression of non-phospho β-catenin showed a significant correlation with positive CTNNB1 mutation status detected by Sanger method (p = 0.025), and poor outcome in COX-2 inhibitor therapy (p = 0.022). In contrast, nuclear expression of β-catenin did not show a significant correlation with either CTNNB1 mutation status (p = 0.43) or outcome of COX-2 inhibitor therapy (p = 0.38). Nuclear expression of non-phospho β-catenin might more appropriately reflect the biological behavior of DF, and immunohistochemical staining with non-phospho β-catenin could serve as a more useful diagnostic and prognostic tool of COX-2 inhibitor therapy for patients with DF.
登录
查看更多内容
影响因子：
45.3
作者：
Ballo, MT;Zagars, GK;Pollock, RA
通讯作者：
Pollock, RA
影响因子：
11.5
作者：
Chugh, Rashmi;Wathen, J. Kyle;Baker, Laurence H.
通讯作者：
Baker, Laurence H.
影响因子：
5.6
作者：
Bhattacharya, B;Dilworth, HP;Montgomery, E
通讯作者：
Montgomery, E
影响因子：
5.3
作者：
Briand, Sylvain;Barbier, Olivier;Gouin, Francois
通讯作者：
Gouin, Francois
影响因子：
6.4
作者：
Gebert, C.;Hardes, J.;Gosheger, G.
通讯作者：
Gosheger, G.